The History of Botulinum Toxin: From medical discovery to modern medicine

The story of botulinum toxin began in the 19th century with sausages.

In the late 18th and early 19th centuries, a number of people in the German region of Württemberg became seriously ill after eating contaminated blood sausages. The local physician and poet Justinus Kerner investigated these outbreaks and published detailed descriptions of the resulting illness between 1817 and 1822. He recognised that a biological poison associated with the spoiled food was responsible and remarkably suggested that the substance might eventually have therapeutic applications.

The term botulism comes from botulus, the Latin word for sausage. In 1895, Belgian microbiologist Émile van Ermengem investigated an outbreak associated with contaminated smoked ham and identified the bacterium responsible, which was initially called Bacillus botulinus and is now known as Clostridium botulinum.

The History of Botulinum Toxin: From laboratory research to medical treatment

During the 20th century, researchers developed a much better understanding of how botulinum toxin affects the nervous system. The toxin interferes with the release of acetylcholine, a chemical messenger involved in communication between nerves and muscles.

This raised the possibility that, in carefully controlled quantities, the toxin could be used to reduce excessive or abnormal muscle activity.

During the 1970s and 1980s, ophthalmologist Dr Alan Scott investigated botulinum toxin type A as a treatment for conditions involving abnormal eye-muscle activity, particularly strabismus (squint).

This work contributed to the development of therapeutic preparations of botulinum toxin type A. In 1989, the US Food and Drug Administration approved a botulinum toxin type A product for certain ophthalmic conditions, including strabismus and blepharospasm.

Further medical applications were subsequently developed, and botulinum toxin is now used in a number of medical specialties.

What exactly is Botox®?

Botox® is a brand name, rather than the generic name for all botulinum toxin treatments.

BOTOX® is a specific formulation of botulinum toxin type A (onabotulinumtoxinA). The product was developed and commercialised by Allergan, the pharmaceutical company that became closely associated with its development.

There are now several different botulinum toxin products available. These have different brand names, formulations and regulatory indications and are separate prescription medicines.

Consequently, "Botox" and "botulinum toxin" are not technically interchangeable terms. Botox® refers specifically to one branded formulation, whereas botulinum toxin describes the active biological substance used in a number of different medicines.

How did botulinum toxin become associated with aesthetic medicine?

The association with aesthetic medicine developed from clinical observations that reducing activity in selected facial muscles could also affect the appearance of expression-related lines.

This led to research into the cosmetic use of botulinum toxin. In 2002, BOTOX® Cosmetic received US FDA approval for the temporary improvement of moderate-to-severe glabellar lines — the vertical lines between the eyebrows.

Since then, different botulinum toxin products have been used in both medical and aesthetic settings, subject to the relevant regulatory approvals in each country.

How does botulinum toxin work?

Botulinum toxin acts at the neuromuscular junction, where nerves communicate with muscles.

It temporarily interferes with the release of acetylcholine from nerve endings. This reduces the signal responsible for muscle contraction in the treated area.

The effect is temporary, because nerve function gradually recovers. The precise effect and duration depend on a number of factors, including the particular medicine used, the treatment area, the dose and the individual patient.

Botulinum toxin in the UK

In the UK, botulinum toxin products are prescription-only medicines. They therefore require an appropriate clinical assessment and prescription by an authorised prescriber.

There are strict restrictions on how prescription-only medicines can be discussed in advertising aimed at the public. CAP Code rule 12.12 prohibits the advertising of prescription-only medicines or prescription-only medical treatments to the public. The restriction applies across advertising media, including websites and social media.

CAP and the ASA have specifically highlighted botulinum toxin products and advise businesses to avoid promoting the medicine itself. Where information is provided on a clinic website, it should be limited, factual and balanced, rather than promotional. CAP guidance also recommends focusing on the consultation, rather than advertising the prescription medicine.

A history shaped by medical research

The development of botulinum toxin is an unusual chapter in medical history. What began with investigations into food poisoning associated with contaminated meat eventually led to a much greater understanding of nerve-muscle communication and the development of carefully controlled medical treatments.

From the observations of Justinus Kerner in the early 19th century, through the identification of Clostridium botulinum by Émile van Ermengem in 1895, to the pioneering therapeutic work of Alan Scott more than 70 years later, the history of botulinum toxin demonstrates how scientific research can transform our understanding of a biological toxin into applications within modern medicine.

Important: This article is provided for general educational information and does not constitute individual medical advice. Whether a prescription-only medicine is appropriate for an individual can only be determined following an appropriate clinical assessment.